Related Experiment Video
Updated: Aug 30, 2026
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Technology evaluation: LErafAON, NeoPharm
João Nuno Moreira1, Sérgio Simões
1Laboratory of Pharmaceutical Technology, Faculty of Pharmacy and Center for Neurosciences and Cell Biology, University of Coimbra, Rua do Norte, Coimbra 3000-295, Portugal. jmoreira@ci.uc.pt
Abstract:
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
Insights
NeoPharm is investigating liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) as a potential cancer therapy. Early trials are exploring its efficacy against solid tumors resistant to standard treatments.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Solid tumors, including those resistant to chemotherapy and radiation, represent a significant unmet medical need.
- Targeting specific molecular pathways, such as the c-Raf kinase, offers a potential strategy for novel cancer therapies.
- Antisense oligodeoxynucleotides (AONs) provide a mechanism to inhibit gene expression at the post-transcriptional level.
Purpose of the Study:
- To evaluate the safety and preliminary efficacy of liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) in patients with various solid tumors.
- To assess the potential of LErafAON in treating tumors refractory to conventional therapies.
Main Methods:
- Phase I/II clinical trials were initiated to assess the safety and tolerability of LErafAON.
- The study involved patients with diverse solid tumor types, including those with resistance to radiation or chemotherapy.
- Ongoing clinical evaluation was conducted from March 2001 to June 2003.
Main Results:
- The abstract does not contain specific results, only that the trials were ongoing as of June 2003.
- Further data collection and analysis were pending.
Conclusions:
- The development of LErafAON represents a novel therapeutic approach for solid tumors.
- Clinical trials are essential to determine the ultimate benefit of this targeted therapy in cancer treatment.
